Hancock Jaffe Laboratories, Inc. Warrants
HJLIW
NASDAQ Capital Market0.56
USD
+0.09
- -
CIK
0001661053
Return %
Stock
S&P500
1Y
211.11
26.53
3Y
202.70
76.60
5Y
-30.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- None
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- DE United States of America
- IPO Date
- May 31, 2018
- CIK
- 0001661053
- Similar Companies
- Business
- Formerly known as Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI), the company was a medical device developer primarily focused on creating bioprosthetic, tissue-based solutions for patients with cardiovascular and vascular conditions. Its product pipeline historically included the VenoValve, intended for chronic venous insufficiency (CVI) of the deep veins, and the CoreoGraft for coronary artery bypass grafting. In a strategic pivot, the organization underwent a corporate rebranding, officially changing its name to enVVeno Medical Corporation and its NASDAQ ticker symbol to NVNO, effective October 1, 2021. This transition marked a concentrated focus on advancing its venous disease programs, particularly the VenoValve, and ceasing further development of the CoreoGraft. The VenoValve, its lead product, is an investigational implant designed to restore proper blood flow for individuals suffering from deep venous CVI, a condition for which the company received FDA Investigational Device Exemption (IDE) approval for a U.S. pivotal trial in 2021. Consequently, the warrants previously traded under HJLIW now correspond to enVVeno Medical Corporation, trading under the new ticker NVNOW.